
CAS 1215197-37-7
:Formel:C18H19F3N4O3
InChl:InChI=1S/C18H19F3N4O3/c19-18(20,21)14-9-25(10-23-14)13(7-11-3-1-2-4-11)16(26)24-15-6-5-12(8-22-15)17(27)28/h5-6,8-11,13H,1-4,7H2,(H,27,28)(H,22,24,26)/t13-/m0/s1
InChI Key:GKMLFBRLRVQVJO-ZDUSSCGKSA-N
SMILES:C1CCC(C1)C[C@@H](C(=O)NC2=NC=C(C=C2)C(=O)O)N3C=C(N=C3)C(F)(F)F
Filtern nach
Reinheitsanteil
0
100
|
0
|
50
|
90
|
95
|
100
5 Produkte gefunden.
- Niedrigster Preis
- Höchster Preis
- Niedrigste Reinheit
- Höchste Reinheit
- Schnellste Lieferung
(S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid
CAS:(S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acidFormel:C18H19F3N4O3Reinheit:99%Molekulargewicht:396.37PF-04991532
CAS:PF-04991532 is a hepatoselective glucokinase activator that reduces plasma glucose and AMP concentrations in the Goto-Kakizaki rat model.Formel:C18H19F3N4O3Reinheit:99.99%Farbe und Form:White SolidMolekulargewicht:396.3637PF 04991532
CAS:PF 04991532 is a cyclopentyl compound that has been shown to have antiviral activity against HIV-1 and hepatitis C virus (HCV) in vitro. It also inhibits the production of inflammatory cytokines such as TNF-α and IL-6, and prevents HCV infection by blocking the interaction of Toll-like receptor 4 with its ligand. PF 04991532 also has an effect on axonal growth in rats with hepatic steatosis. PF 04991532 is administered orally, at a dose of 10 mg/kg once daily for 28 days. This treatment was found to be safe and well tolerated. There were no significant changes in pharmacokinetic parameters between the treatment group and the placebo group. The drug is not metabolized by cytochrome P450 enzymes, but it undergoes glucuronidation after being metabolized by other enzymes, resulting in a glucuronide conjugate (PF04991532-G).Formel:C18H19F3N4O3Reinheit:Min. 95%Molekulargewicht:396.36 g/mol





